Your Zip Code Should Not Determine Your Treatment: The Borough-by-Borough Breakdown of HIV Medication Coverage in New York

Consider two New Yorkers. Both are HIV-positive. Both are enrolled in Medicaid managed care. Both have been stable on the same antiretroviral regimen for three years. One lives in Crown Heights, Brooklyn. The other lives in Woodhaven, Queens.

Same state. Same program. Different managed care organization. Different formulary. Different prior authorization requirements. And, as of last year, different medications—because when the Queens resident's plan declined to cover her existing regimen without a new round of prior authorization documentation that her clinic lacked the staffing to produce on time, she was switched to an alternative that her physician considered a second-line choice.

This is not a hypothetical. Variations of this scenario play out across New York City with a regularity that advocates describe as a quiet, ongoing crisis—one that receives far less public attention than it deserves precisely because its effects are dispersed across individual cases rather than concentrated in a single, visible failure.

How the Patchwork Gets Built

Understanding why coverage varies by geography requires a brief tour of how Medicaid managed care works in New York State.

Rather than operating as a single unified program, New York Medicaid contracts with multiple managed care organizations—MCOs—to administer benefits for enrolled members. These MCOs operate under broad state guidelines but maintain significant latitude in constructing their formularies: the lists of drugs they will cover, the tiers at which they place those drugs, and the prior authorization criteria they apply.

The MCOs available to a Medicaid enrollee depend on their county of residence. In New York City, this means borough—and the plans operating in the Bronx do not perfectly overlap with those operating in Staten Island. A beneficiary who moves from one borough to another may find themselves involuntarily transitioning to a new MCO whose formulary does not include their current medication.

For most health conditions, a formulary switch is an inconvenience. For HIV-positive patients on carefully calibrated antiretroviral regimens, it can represent a genuine clinical threat. Antiretrovirals are not interchangeable in the way that, say, blood pressure medications might be. Resistance patterns, side effect profiles, pill burden, and the specific dynamics of a patient's immune history all factor into which regimen is optimal for a given individual. A switch that looks administratively routine can be clinically consequential.

"We've had patients who had been undetectable for years destabilize after a forced formulary switch," said one HIV pharmacist at a Manhattan clinic who requested anonymity because they were not authorized to speak publicly. "The plan sees a substitutable generic. The clinician sees a patient whose viral suppression we worked for years to achieve."

Commercial Insurance Is Not a Safe Harbor

It would be tempting to assume that commercial insurance—the kind obtained through an employer or purchased on the individual market—offers a more consistent landscape. The data suggests otherwise.

Commercial plans sold through the New York State of Health marketplace vary substantially in their HIV drug coverage, specialty pharmacy requirements, and step therapy protocols. Step therapy—sometimes called "fail first"—requires patients to try and fail on a cheaper or older medication before a plan will authorize the one their physician originally prescribed. In HIV care, where treatment history and resistance patterns make first-line medication choices critical, step therapy requirements can create genuine harm.

New York State enacted legislation in 2017 requiring commercial insurers to allow physicians to request exceptions to step therapy requirements. The law was a meaningful advance. But the exception process itself can be time-consuming, documentation-heavy, and opaque—placing the administrative burden squarely on already-stretched clinic staff and, ultimately, on patients who must wait while approvals are sought.

Geography intersects with commercial coverage in a different but equally significant way: access to the specialty pharmacies that dispense many antiretrovirals is not evenly distributed across the five boroughs. Several plans require members to use specific specialty pharmacy networks, and those networks have physical footprints concentrated in Manhattan and certain parts of Brooklyn, leaving patients in the Bronx, Queens, and Staten Island navigating longer travel times, inconsistent delivery logistics, or both.

The Data Behind the Disparity

A review of formulary data published by New York State Medicaid MCOs, cross-referenced with pharmacy access mapping conducted by HIV advocacy organizations, illustrates the scope of the problem in concrete terms.

Of the antiretroviral drugs listed on the World Health Organization's essential medicines list and currently in common use in the United States, a significant subset appears on some MCO formularies operating in New York City but not others. Long-acting injectable antiretrovirals—a treatment modality that has transformed adherence for many patients—are covered by some plans as a standard benefit and subject to complex prior authorization requirements by others, with no clinical rationale for the difference.

Approval timelines for prior authorization requests for HIV medications vary from as few as three business days at the most responsive plans to more than three weeks at the slowest—a gap that, for a patient who has run out of medication or experienced a coverage disruption, is not an abstraction but a window of dangerous non-adherence.

Breaking this data down by borough reveals patterns consistent with broader health equity concerns. The Bronx, which carries the city's highest HIV burden and the highest concentration of Medicaid-enrolled HIV-positive residents, is served by a MCO mix that advocacy organizations have flagged as having, on average, more restrictive prior authorization criteria for HIV medications than plans dominant in lower-burden boroughs.

What Patients Are Left to Navigate

The practical consequences fall heaviest on the people least equipped to absorb them. Patients with unstable housing, those with limited English proficiency, those working multiple jobs, and those managing co-occurring mental health conditions are least likely to have the time, resources, or support to successfully contest a prior authorization denial or navigate a specialty pharmacy requirement that conflicts with their daily reality.

Rodrigo, a 38-year-old HIV-positive man from the Bronx who works in building maintenance, described spending portions of three consecutive weekends on the phone with his insurance plan attempting to resolve a coverage dispute over his antiretroviral. "Every time I called, it was a different person, a different answer," he said. "I missed doses. I didn't want to. I had no choice."

His viral load, which had been undetectable, rebounded during the coverage gap. It took months of re-engagement to return to suppression.

Policy Levers That Could Change This

Several policy interventions have demonstrated promise in other states and deserve serious consideration in New York.

A uniform HIV antiretroviral formulary for all Medicaid MCOs operating in the state—modeled on approaches piloted in California and Washington—would eliminate the arbitrary variation that currently makes treatment continuity a geographic lottery. The New York State Department of Health has the regulatory authority to require such standardization; advocates are pressing for it to exercise that authority.

Strengthening and streamlining the prior authorization exception process—including establishing enforceable timelines and automatic approvals when documentation is submitted by an HIV specialist—would reduce the administrative attrition that currently causes patients to abandon appeals they have every right to win.

Finally, investment in specialty pharmacy infrastructure in underserved boroughs, potentially through the Ryan White HIV/AIDS Program or city capital funding, would address the access gap that geography currently imposes on patients who need consistent, reliable medication delivery.

New York has led the nation in its commitment to ending the HIV epidemic. Allowing a patient's zip code to determine the quality of their treatment is incompatible with that commitment. The tools to fix this exist. The question is whether the political will to deploy them can be summoned before more New Yorkers pay the price of a system designed for administrative convenience rather than clinical care.